NASDAQ:EVFM

Evofem Biosciences (EVFM) Stock Price, News & Analysis

Evofem Biosciences logo
$0.0043 0.00 (0.00%)
As of 11/17/2026 03:59 PM Eastern

About Evofem Biosciences Stock (NASDAQ:EVFM)

Advanced

Key Stats

Today's Range
$0.0043
▼
$0.0066
50-Day Range
$0.0043
▼
$0.0082
52-Week Range
$0.0008
▼
$0.0136
Volume
2.70 million shs
Average Volume
208,086 shs
Market Capitalization
$569.88 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evofem Biosciences is a biopharmaceutical company focused on developing and commercializing products for women’s reproductive health. Its best-known product is Phexxi, a prescription, non-hormonal contraceptive vaginal gel used on demand before intercourse.

Approved by the U.S. Food and Drug Administration in 2020, Phexxi works by maintaining the vagina’s natural acidic pH, which can reduce sperm movement. The product is intended for use in the United States.

Evofem has also pursued development of investigational products addressing sexually transmitted infections, including a candidate studied for the prevention of chlamydia and gonorrhea. These candidates are distinct from Phexxi and should not be understood as approved treatments.

AI Generated. May Contain Errors.

Receive EVFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EVFM Stock News Headlines

Quarterly Profit Could Change The Case For Evofem Biosciences Stock
Evofem amends key convertible note financing terms
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Evofem Biosciences Inc. (EVFM)
See More Headlines

EVFM Stock Analysis - Frequently Asked Questions

Evofem Biosciences' stock was trading at $0.0092 at the beginning of the year. Since then, EVFM shares have decreased by 53.3% and is now trading at $0.0043.

Evofem Biosciences, Inc. (NASDAQ:EVFM) issued its quarterly earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative trailing twelve-month return on equity of 91.97% and a negative net margin of 46.42%.

Evofem Biosciences's stock reverse split before market open on Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Vaxart (VXRT), Palantir Technologies (PLTR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Company Calendar

Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:EVFM
CIK
1618835
Employees
29
Year Founded
2007

Profitability

EPS (Trailing Twelve Months)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$52.98 million
Net Margins
-46.42%
Pretax Margin
-46.42%
Return on Equity
-91.97%
Return on Assets
-61.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.11
Quick Ratio
0.09

Sales & Book Value

Annual Sales
$11.39 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.64) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
132,530,000
Free Float
113,118,000
Market Cap
$569.88 thousand
Optionable
Not Optionable
Beta
-1.41

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:EVFM) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners